Payment overview · 2025
General Payments
$2,185.03
96 reported records · 29 companies
Healthcare provider profile · identity verified
Robert Joseph Bloomberg, MD
Allopathic & Osteopathic Physicians|Internal Medicine · TEMPE, AZ · NPI 1952375362
Verified facts
What the public records show
CMS Open Payments records show Robert Joseph Bloomberg, MD received $2,185.03 in general payments during 2025 across 96 reported records.
Novo Nordisk Inc accounted for 13.2% of that reported general-payment amount.
The Open Payments records used for this analysis explicitly named 52 associated products.
A separate comparison found the same explicitly named product in public Medicare Part D data: Eliquis, Farxiga, Mounjaro, Ozempic, Paxlovid, Rybelsus, Synthroid, Trelegy Ellipta.
ABBVIE INC. reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported SYNTHROID as an associated drug or biological on 10655 records involving 4881 distinct recipient NPIs. Public Medicare Part D data also shows 37 claims for Synthroid by this doctor in 2024.
Amgen Inc. reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported PROLIA as an associated drug or biological on 20867 records involving 11744 distinct recipient NPIs. Public Medicare Part D data also shows 16 claims for Prolia by this doctor in 2024.
Astellas Pharma US Inc reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported Myrbetriq as an associated drug or biological on 16 records involving 16 distinct recipient NPIs. Public Medicare Part D data also shows 20 claims for Myrbetriq by this doctor in 2024.
AstraZeneca Pharmaceuticals LP reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported FARXIGA as an associated drug or biological on 106133 records involving 42906 distinct recipient NPIs. Public Medicare Part D data also shows 39 claims for Farxiga by this doctor in 2024.
AstraZeneca Pharmaceuticals LP reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported SYMBICORT as an associated drug or biological on 71 records involving 51 distinct recipient NPIs. Public Medicare Part D data also shows 12 claims for Symbicort by this doctor in 2024.
GlaxoSmithKline, LLC. reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported TRELEGY ELLIPTA as an associated drug or biological on 131532 records involving 37148 distinct recipient NPIs. Public Medicare Part D data also shows 37 claims for Trelegy Ellipta by this doctor in 2024.
Lilly USA, LLC reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported MOUNJARO as an associated drug or biological on 186719 records involving 66436 distinct recipient NPIs. Public Medicare Part D data also shows 60 claims for Mounjaro by this doctor in 2024.
Novartis Pharmaceuticals Corporation reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported ENTRESTO as an associated drug or biological on 9346 records involving 6254 distinct recipient NPIs. Public Medicare Part D data also shows 12 claims for Entresto by this doctor in 2024.
Novo Nordisk Inc reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported Ozempic as an associated drug or biological on 261625 records involving 77793 distinct recipient NPIs. Public Medicare Part D data also shows 55 claims for Ozempic by this doctor in 2024.
Novo Nordisk Inc reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported Rybelsus as an associated drug or biological on 161257 records involving 55409 distinct recipient NPIs. Public Medicare Part D data also shows 15 claims for Rybelsus by this doctor in 2024.
PFIZER INC. reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported ELIQUIS as an associated drug or biological on 87112 records involving 36032 distinct recipient NPIs. Public Medicare Part D data also shows 99 claims for Eliquis by this doctor in 2024.
PFIZER INC. reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported PAXLOVID as an associated drug or biological on 24465 records involving 15715 distinct recipient NPIs. Public Medicare Part D data also shows 47 claims for Paxlovid by this doctor in 2024.
These records do not establish that a payment influenced prescribing or medical care.
Separate record types
Research & Ownership
Research Payments (direct recipient): not present in the loaded data
Associated Research Funding (for example, named PI): not present in the loaded data
Ownership / Investment: not present in the loaded data
These categories are never added into the General Payments headline. Associated research funding must not be described as money the doctor personally received unless the source record supports that conclusion.
Who paid this doctor?
Companies in 2025 General Payments
| Reported company | Canonical company | Amount | Share | Records | Year |
|---|---|---|---|---|---|
| Novo Nordisk Inc | Unresolved — no canonical attribution shown | $289.21 | 13.2% | 11 | 2025 |
| PFIZER INC. | Unresolved — no canonical attribution shown | $201.47 | 9.2% | 13 | 2025 |
| Eisai Inc. | Unresolved — no canonical attribution shown | $198.49 | 9.1% | 8 | 2025 |
| Inspire Medical Systems, Inc. | Unresolved — no canonical attribution shown | $169.09 | 7.7% | 2 | 2025 |
| AstraZeneca Pharmaceuticals LP | Unresolved — no canonical attribution shown | $150.31 | 6.9% | 6 | 2025 |
| Teleflex LLC | Unresolved — no canonical attribution shown | $146.88 | 6.7% | 1 | 2025 |
| GlaxoSmithKline, LLC. | Unresolved — no canonical attribution shown | $142.74 | 6.5% | 10 | 2025 |
| Abbott Laboratories | Unresolved — no canonical attribution shown | $106.23 | 4.9% | 6 | 2025 |
| ABBVIE INC. | Unresolved — no canonical attribution shown | $86.30 | 4.0% | 4 | 2025 |
| Astellas Pharma US Inc | Unresolved — no canonical attribution shown | $71.56 | 3.3% | 3 | 2025 |
| Lilly USA, LLC | Unresolved — no canonical attribution shown | $68.15 | 3.1% | 4 | 2025 |
| Amgen Inc. | Unresolved — no canonical attribution shown | $64.94 | 3.0% | 4 | 2025 |
| Otsuka America Pharmaceutical, Inc. | Unresolved — no canonical attribution shown | $56.22 | 2.6% | 3 | 2025 |
| Dexcom, Inc. | Unresolved — no canonical attribution shown | $47.98 | 2.2% | 2 | 2025 |
| Sumitomo Pharma America, Inc. | Unresolved — no canonical attribution shown | $45.83 | 2.1% | 2 | 2025 |
| Novartis Pharmaceuticals Corporation | Unresolved — no canonical attribution shown | $39.57 | 1.8% | 2 | 2025 |
| Cleerly, Inc. | Unresolved — no canonical attribution shown | $38.80 | 1.8% | 1 | 2025 |
| Viatris Specialty LLC | Unresolved — no canonical attribution shown | $32.08 | 1.5% | 2 | 2025 |
| Medicure Pharma Inc. | Unresolved — no canonical attribution shown | $30.30 | 1.4% | 1 | 2025 |
| Merck Sharp & Dohme LLC | Unresolved — no canonical attribution shown | $29.68 | 1.4% | 2 | 2025 |
| Aimmune Therapeutics, Inc. | Unresolved — no canonical attribution shown | $28.05 | 1.3% | 1 | 2025 |
| SHIELD THERAPEUTICS INC | Unresolved — no canonical attribution shown | $25.38 | 1.2% | 1 | 2025 |
| Kestra Medical Technology Services, Inc. | Unresolved — no canonical attribution shown | $23.04 | 1.1% | 1 | 2025 |
| Boehringer Ingelheim Pharmaceuticals, Inc. | Unresolved — no canonical attribution shown | $20.00 | 0.9% | 1 | 2025 |
| Bayer Healthcare Pharmaceuticals Inc. | Unresolved — no canonical attribution shown | $19.29 | 0.9% | 1 | 2025 |
| Medtronic, Inc. |
Medtronic, Inc. exact · evidence 2025-07-22 |
$15.20 | 0.7% | 1 | 2025 |
| Salix Pharmaceuticals, a division of Bausch Health US, LLC | Unresolved — no canonical attribution shown | $14.88 | 0.7% | 1 | 2025 |
| Boston Scientific Corporation | Unresolved — no canonical attribution shown | $14.75 | 0.7% | 1 | 2025 |
| Echosens North America, Inc. | Unresolved — no canonical attribution shown | $8.61 | 0.4% | 1 | 2025 |
What were the payments for?
Payment categories
| Category | Amount | Records |
|---|---|---|
| Food and Beverage | $2,185.03 | 96 |
A meal, consulting fee, royalty, and travel payment describe different kinds of reported relationships and should not be interpreted as equivalent.
Analysis 1 · Payment-linked products
Products named in Open Payments records
| Reported product | Type | Reported company | Related amount* | Records | Year |
|---|---|---|---|---|---|
| Leqembi Normalized: leqembi |
Drug | Eisai Inc. | $198.49 | 8 | 2025 |
Source payment records
|
|||||
| INSPIRE Normalized: inspire |
Device | Inspire Medical Systems, Inc. | $169.09 | 2 | 2025 |
Source payment records
|
|||||
| BARRIGEL Normalized: barrigel |
Device | Teleflex LLC | $146.88 | 1 | 2025 |
Source payment records
|
|||||
| AIRSUPRA Normalized: airsupra |
Drug | AstraZeneca Pharmaceuticals LP | $119.77 | 4 | 2025 |
Source payment records
|
|||||
| NURTEC ODT Normalized: nurtec odt |
Drug | PFIZER INC. | $114.15 | 8 | 2025 |
Source payment records
|
|||||
| TRELEGY ELLIPTA Normalized: trelegy ellipta |
Drug | GlaxoSmithKline, LLC. | $97.21 | 5 | 2025 |
Source payment records
|
|||||
| FREESTYLE LIBRE 3 Normalized: freestyle libre 3 |
Device | Abbott Laboratories | $92.02 | 5 | 2025 |
Source payment records
|
|||||
| FASENRA Normalized: fasenra |
Biological | AstraZeneca Pharmaceuticals LP | $89.35 | 2 | 2025 |
Source payment records
|
|||||
| FARXIGA Normalized: farxiga |
Drug | AstraZeneca Pharmaceuticals LP | $87.89 | 2 | 2025 |
Source payment records
|
|||||
| ABRYSVO Normalized: abrysvo |
Biological | PFIZER INC. | $87.32 | 5 | 2025 |
Source payment records
|
|||||
| COMIRNATY Normalized: comirnaty |
Biological | PFIZER INC. | $87.32 | 5 | 2025 |
Source payment records
|
|||||
| PREVNAR 20 Normalized: prevnar 20 |
Biological | PFIZER INC. | $87.32 | 5 | 2025 |
Source payment records
|
|||||
| BREZTRI Normalized: breztri |
Drug | AstraZeneca Pharmaceuticals LP | $73.35 | 1 | 2025 |
Source payment records
|
|||||
| Veozah Normalized: veozah |
Drug | Astellas Pharma US Inc | $71.56 | 3 | 2025 |
Source payment records
|
|||||
| PREVNAR 13 Normalized: prevnar 13 |
Biological | PFIZER INC. | $67.00 | 3 | 2025 |
Source payment records
|
|||||
| Ozempic Normalized: ozempic |
Drug | Novo Nordisk Inc | $63.04 | 4 | 2025 |
Source payment records
|
|||||
| Rybelsus Normalized: rybelsus |
Drug | Novo Nordisk Inc | $63.04 | 4 | 2025 |
Source payment records
|
|||||
| REXULTI Normalized: rexulti |
Drug | Otsuka America Pharmaceutical, Inc. | $56.22 | 3 | 2025 |
Source payment records
|
|||||
| ZAVZPRET Normalized: zavzpret |
Drug | PFIZER INC. | $50.21 | 3 | 2025 |
Source payment records
|
|||||
| EVENITY Normalized: evenity |
Biological | Amgen Inc. | $48.10 | 3 | 2025 |
Source payment records
|
|||||
| ELIQUIS Normalized: eliquis |
Drug | PFIZER INC. | $47.99 | 3 | 2025 |
Source payment records
|
|||||
| Dexcom G6 Transmitter Normalized: dexcom g6 transmitter |
Medical Supply | Dexcom, Inc. | $47.98 | 2 | 2025 |
Source payment records
|
|||||
| GEMTESA Normalized: gemtesa |
Drug | Sumitomo Pharma America, Inc. | $45.83 | 2 | 2025 |
Source payment records
|
|||||
| SHINGRIX Normalized: shingrix |
Biological | GlaxoSmithKline, LLC. | $45.53 | 5 | 2025 |
Source payment records
|
|||||
| JARDIANCE Normalized: jardiance |
Drug | Boehringer Ingelheim Pharmaceuticals, Inc., Lilly USA, LLC | $39.96 | 2 | 2025 |
Source payment records
|
|||||
| LEQVIO Normalized: leqvio |
Drug | Novartis Pharmaceuticals Corporation | $39.57 | 2 | 2025 |
Source payment records
|
|||||
| Cleerly Ischemia Normalized: cleerly ischemia |
Device | Cleerly, Inc. | $38.80 | 1 | 2025 |
Source payment records
|
|||||
| Cleerly Labs Normalized: cleerly labs |
Device | Cleerly, Inc. | $38.80 | 1 | 2025 |
Source payment records
|
|||||
| Wegovy Normalized: wegovy |
Drug | Novo Nordisk Inc | $36.37 | 3 | 2025 |
Source payment records
|
|||||
| QULIPTA Normalized: qulipta |
Drug | ABBVIE INC. | $34.55 | 1 | 2025 |
Source payment records
|
|||||
| UBRELVY Normalized: ubrelvy |
Drug | ABBVIE INC. | $34.55 | 1 | 2025 |
Source payment records
|
|||||
| KISUNLA Normalized: kisunla |
Drug | Lilly USA, LLC | $33.02 | 2 | 2025 |
Source payment records
|
|||||
| YUPELRI Normalized: yupelri |
Drug | Viatris Specialty LLC | $32.08 | 2 | 2025 |
Source payment records
|
|||||
| Zypitamag Normalized: zypitamag |
Drug | Medicure Pharma Inc. | $30.30 | 1 | 2025 |
Source payment records
|
|||||
| CAPVAXIVE Normalized: capvaxive |
Biological | Merck Sharp & Dohme LLC | $29.68 | 2 | 2025 |
Source payment records
|
|||||
| GARDASIL 9 Normalized: gardasil 9 |
Biological | Merck Sharp & Dohme LLC | $29.68 | 2 | 2025 |
Source payment records
|
|||||
| ZENPEP Normalized: zenpep |
Drug | Aimmune Therapeutics, Inc. | $28.05 | 1 | 2025 |
Source payment records
|
|||||
| ACCRUFER Normalized: accrufer |
Drug | SHIELD THERAPEUTICS INC | $25.38 | 1 | 2025 |
Source payment records
|
|||||
| Assure WCD Normalized: assure wcd |
Device | Kestra Medical Technology Services, Inc. | $23.04 | 1 | 2025 |
Source payment records
|
|||||
| BOTOX Normalized: botox |
Biological | ABBVIE INC. | $21.76 | 1 | 2025 |
Source payment records
|
|||||
| Kerendia Normalized: kerendia |
Drug | Bayer Healthcare Pharmaceuticals Inc. | $19.29 | 1 | 2025 |
Source payment records
|
|||||
| AREXVY Normalized: arexvy |
Biological | GlaxoSmithKline, LLC. | $19.28 | 1 | 2025 |
Source payment records
|
|||||
| REPATHA Normalized: repatha |
Biological | Amgen Inc. | $16.84 | 1 | 2025 |
Source payment records
|
|||||
| PAXLOVID Normalized: paxlovid |
Drug | PFIZER INC. | $15.95 | 2 | 2025 |
Source payment records
|
|||||
| SYNTHROID Normalized: synthroid |
Drug | ABBVIE INC. | $15.88 | 1 | 2025 |
Source payment records
|
|||||
| INTELLIS ADAPTIVESTIM Normalized: intellis adaptivestim |
Device | Medtronic, Inc. | $15.20 | 1 | 2025 |
Source payment records
|
|||||
| MOUNJARO Normalized: mounjaro |
Drug | Lilly USA, LLC | $15.17 | 1 | 2025 |
Source payment records
|
|||||
| XIFAXAN Normalized: xifaxan |
Drug | Salix Pharmaceuticals, a division of Bausch Health US, LLC | $14.88 | 1 | 2025 |
Source payment records
|
|||||
| WATCHMAN FLX Normalized: watchman flx |
Device | Boston Scientific Corporation | $14.75 | 1 | 2025 |
Source payment records
|
|||||
| AVEIR Normalized: aveir |
Device | Abbott Laboratories | $14.21 | 1 | 2025 |
Source payment records
|
|||||
| VRAYLAR Normalized: vraylar |
Drug | ABBVIE INC. | $14.11 | 1 | 2025 |
Source payment records
|
|||||
| Fibroscan Normalized: fibroscan |
Device | Echosens North America, Inc. | $8.61 | 1 | 2025 |
Source payment records
|
|||||
* Product-associated amounts are non-additive because one payment record may name more than one product.
These products were named on specific Open Payments records. A named product does not show that the payment influenced treatment or prescribing.
Public prescribing for products named in payments
| Open Payments product | Payment year | Part D brand | Part D year | Claims | Match method | Source |
|---|---|---|---|---|---|---|
| ELIQUIS eliquis |
2025 | Eliquis | 2024 | 99 | exact normalized | Medicare Part D |
| FARXIGA farxiga |
2025 | Farxiga | 2024 | 39 Beneficiary count suppressed |
exact normalized | Medicare Part D |
| MOUNJARO mounjaro |
2025 | Mounjaro | 2024 | 60 Beneficiary count suppressed |
exact normalized | Medicare Part D |
| Ozempic ozempic |
2025 | Ozempic | 2024 | 55 | exact normalized | Medicare Part D |
| PAXLOVID paxlovid |
2025 | Paxlovid | 2024 | 47 | exact normalized | Medicare Part D |
| Rybelsus rybelsus |
2025 | Rybelsus | 2024 | 15 Beneficiary count suppressed |
exact normalized | Medicare Part D |
| SYNTHROID synthroid |
2025 | Synthroid | 2024 | 37 Beneficiary count suppressed |
exact normalized | Medicare Part D |
| TRELEGY ELLIPTA trelegy ellipta |
2025 | Trelegy Ellipta | 2024 | 37 | exact normalized | Medicare Part D |
The presence of the same drug in both datasets does not show that a payment caused or influenced a prescription.
Analysis 2 · Same-company prescribing overlap
Drugs reported in other payments from the same company that also appear in Medicare Part D
This analysis is independent from products named on this doctor’s individual payment records. A row appears only when the exact Open Payments reporting entity paid this doctor, that same reporting entity reported the drug or biological on at least 10 loaded General Payment records involving at least 2 distinct recipient NPIs, and this doctor has the same non-generic brand in public Part D data. This does not mean the company owns or manufactures the drug.
| Paying company | Payment year | Drug reported by same entity | Open Payments evidence | Part D | Claims | Beneficiaries |
|---|---|---|---|---|---|---|
| ABBVIE INC. Exact reporting entity; no affiliate inference |
2025 | SYNTHROID open payments reported associated product |
CMS Open Payments — General Payments 10655 supporting records · 4881 recipient NPIs · example record 1201352636 |
Synthroid · 2024 Exact normalized brand match · 1 Part D row |
37 | suppressed by CMS |
| Amgen Inc. Exact reporting entity; no affiliate inference |
2025 | PROLIA open payments reported associated product |
CMS Open Payments — General Payments 20867 supporting records · 11744 recipient NPIs · example record 1226874448 |
Prolia · 2024 Exact normalized brand match · 1 Part D row |
16 | suppressed by CMS |
| Astellas Pharma US Inc Exact reporting entity; no affiliate inference |
2025 | Myrbetriq open payments reported associated product |
CMS Open Payments — General Payments 16 supporting records · 16 recipient NPIs · example record 1238599014 |
Myrbetriq · 2024 Exact normalized brand match · 1 Part D row |
20 | suppressed by CMS |
| AstraZeneca Pharmaceuticals LP Exact reporting entity; no affiliate inference |
2025 | FARXIGA open payments reported associated product |
CMS Open Payments — General Payments 106133 supporting records · 42906 recipient NPIs · example record 1206131362 |
Farxiga · 2024 Exact normalized brand match · 1 Part D row |
39 | suppressed by CMS |
| AstraZeneca Pharmaceuticals LP Exact reporting entity; no affiliate inference |
2025 | SYMBICORT open payments reported associated product |
CMS Open Payments — General Payments 71 supporting records · 51 recipient NPIs · example record 1206132610 |
Symbicort · 2024 Exact normalized brand match · 1 Part D row |
12 | suppressed by CMS |
| GlaxoSmithKline, LLC. Exact reporting entity; no affiliate inference |
2025 | TRELEGY ELLIPTA open payments reported associated product |
CMS Open Payments — General Payments 131532 supporting records · 37148 recipient NPIs · example record 1190332369 |
Trelegy Ellipta · 2024 Exact normalized brand match · 1 Part D row |
37 | 11 |
| Lilly USA, LLC Exact reporting entity; no affiliate inference |
2025 | MOUNJARO open payments reported associated product |
CMS Open Payments — General Payments 186719 supporting records · 66436 recipient NPIs · example record 1186464455 |
Mounjaro · 2024 Exact normalized brand match · 1 Part D row |
60 | suppressed by CMS |
| Novartis Pharmaceuticals Corporation Exact reporting entity; no affiliate inference |
2025 | ENTRESTO open payments reported associated product |
CMS Open Payments — General Payments 9346 supporting records · 6254 recipient NPIs · example record 1200004797 |
Entresto · 2024 Exact normalized brand match · 1 Part D row |
12 | suppressed by CMS |
| Novo Nordisk Inc Exact reporting entity; no affiliate inference |
2025 | Ozempic open payments reported associated product |
CMS Open Payments — General Payments 261625 supporting records · 77793 recipient NPIs · example record 1188130076 |
Ozempic · 2024 Exact normalized brand match · 1 Part D row |
55 | 12 |
| Novo Nordisk Inc Exact reporting entity; no affiliate inference |
2025 | Rybelsus open payments reported associated product |
CMS Open Payments — General Payments 161257 supporting records · 55409 recipient NPIs · example record 1188130076 |
Rybelsus · 2024 Exact normalized brand match · 1 Part D row |
15 | suppressed by CMS |
| PFIZER INC. Exact reporting entity; no affiliate inference |
2025 | ELIQUIS open payments reported associated product |
CMS Open Payments — General Payments 87112 supporting records · 36032 recipient NPIs · example record 1228794063 |
Eliquis · 2024 Exact normalized brand match · 1 Part D row |
99 | 25 |
| PFIZER INC. Exact reporting entity; no affiliate inference |
2025 | PAXLOVID open payments reported associated product |
CMS Open Payments — General Payments 24465 supporting records · 15715 recipient NPIs · example record 1228794432 |
Paxlovid · 2024 Exact normalized brand match · 1 Part D row |
47 | 45 |
These facts do not show that a payment was for the drug, that the company owns or manufactures the drug, or that a payment caused or influenced prescribing.
Public Medicare Part D data
Provider-and-drug rows loaded for 2024
| Brand | Generic | Claims | Beneficiaries |
|---|---|---|---|
| Rosuvastatin Calcium | Rosuvastatin Calcium | 438 | 130 |
| Atorvastatin Calcium | Atorvastatin Calcium | 387 | 112 |
| Amlodipine Besylate | Amlodipine Besylate | 361 | 97 |
| Levothyroxine Sodium | Levothyroxine Sodium | 319 | 87 |
| Valsartan | Valsartan | 283 | 73 |
| Losartan Potassium | Losartan Potassium | 195 | 58 |
| Ezetimibe | Ezetimibe | 177 | 58 |
| Lisinopril | Lisinopril | 152 | 47 |
| Metformin Hcl | Metformin Hcl | 136 | 42 |
| Tamsulosin Hcl | Tamsulosin Hcl | 134 | 39 |
| Pantoprazole Sodium | Pantoprazole Sodium | 105 | 41 |
| Eliquis | Apixaban | 99 | 25 |
| Metformin Hcl Er | Metformin Hcl | 96 | 31 |
| Montelukast Sodium | Montelukast Sodium | 94 | 29 |
| Atenolol | Atenolol | 91 | 27 |
| Furosemide | Furosemide | 85 | 28 |
| Metoprolol Succinate | Metoprolol Succinate | 84 | 25 |
| Famotidine | Famotidine | 83 | 21 |
| Azithromycin | Azithromycin | 81 | 61 |
| Duloxetine Hcl | Duloxetine Hcl | 80 | 19 |
| Metoprolol Tartrate | Metoprolol Tartrate | 80 | 30 |
| Cephalexin | Cephalexin | 77 | 53 |
| Allopurinol | Allopurinol | 75 | 23 |
| Gabapentin | Gabapentin | 73 | 26 |
| Carvedilol | Carvedilol | 71 | 20 |
| Doxycycline Monohydrate | Doxycycline Monohydrate | 70 | 46 |
| Potassium Chloride | Potassium Chloride | 70 | 23 |
| Alendronate Sodium | Alendronate Sodium | 69 | 31 |
| Finasteride | Finasteride | 69 | 24 |
| Prednisone | Prednisone | 68 | 32 |
| Simvastatin | Simvastatin | 64 | 21 |
| Hydrochlorothiazide | Hydrochlorothiazide | 63 | 17 |
| Meloxicam | Meloxicam | 62 | 22 |
| Bumetanide | Bumetanide | 61 | 18 |
| Mounjaro | Tirzepatide | 60 | suppressed |
| Omeprazole | Omeprazole | 60 | 20 |
| Escitalopram Oxalate | Escitalopram Oxalate | 59 | 17 |
| Sertraline Hcl | Sertraline Hcl | 57 | 17 |
| Trazodone Hcl | Trazodone Hcl | 57 | 16 |
| Pravastatin Sodium | Pravastatin Sodium | 56 | 15 |
| Ozempic | Semaglutide | 55 | 12 |
| Xarelto | Rivaroxaban | 52 | 12 |
| Amoxicillin-Clavulanate Potass | Amoxicillin/Potassium Clav | 51 | 30 |
| Albuterol Sulfate Hfa | Albuterol Sulfate | 50 | 29 |
| Donepezil Hcl | Donepezil Hcl | 49 | 16 |
| Ondansetron Odt | Ondansetron | 47 | 27 |
| Paxlovid | Nirmatrelvir/Ritonavir | 47 | 45 |
| Spironolactone | Spironolactone | 47 | 18 |
| Lovastatin | Lovastatin | 44 | 11 |
| Azelastine Hcl | Azelastine Hcl | 43 | 22 |
| Cyclobenzaprine Hcl | Cyclobenzaprine Hcl | 43 | 23 |
| Ramipril | Ramipril | 43 | 12 |
| Cefdinir | Cefdinir | 42 | 35 |
| Folic Acid | Folic Acid | 42 | suppressed |
| Methylprednisolone | Methylprednisolone | 42 | 30 |
| Bupropion Xl | Bupropion Hcl | 40 | suppressed |
| Memantine Hcl | Memantine Hcl | 40 | 13 |
| Farxiga | Dapagliflozin Propanediol | 39 | suppressed |
| Glimepiride | Glimepiride | 38 | 12 |
| Mupirocin | Mupirocin | 37 | 33 |
| Synthroid | Levothyroxine Sodium | 37 | suppressed |
| Trelegy Ellipta | Fluticasone/Umeclidin/Vilanter | 37 | 11 |
| Carbidopa-Levodopa | Carbidopa/Levodopa | 36 | suppressed |
| Lantus Solostar | Insulin Glargine,hum.Rec.Anlog | 36 | 11 |
| Hydralazine Hcl | Hydralazine Hcl | 34 | 11 |
| Citalopram Hbr | Citalopram Hydrobromide | 33 | suppressed |
| Clopidogrel | Clopidogrel Bisulfate | 32 | suppressed |
| Terazosin Hcl | Terazosin Hcl | 32 | suppressed |
| Tizanidine Hcl | Tizanidine Hcl | 31 | suppressed |
| Fluticasone Propionate | Fluticasone Propionate | 30 | suppressed |
| Labetalol Hcl | Labetalol Hcl | 30 | suppressed |
| Repatha Sureclick | Evolocumab | 30 | suppressed |
| Venlafaxine Hcl Er | Venlafaxine Hcl | 30 | suppressed |
| Valsartan-Hydrochlorothiazide | Valsartan/Hydrochlorothiazide | 29 | suppressed |
| Warfarin Sodium | Warfarin Sodium | 29 | suppressed |
| Mirtazapine | Mirtazapine | 28 | 12 |
| Olmesartan Medoxomil | Olmesartan Medoxomil | 27 | suppressed |
| Ofloxacin | Ofloxacin | 26 | 20 |
| Nifedipine Er | Nifedipine | 25 | suppressed |
| Valacyclovir | Valacyclovir Hcl | 25 | 18 |
| Levocetirizine Dihydrochloride | Levocetirizine Dihydrochloride | 24 | suppressed |
| Pregabalin | Pregabalin | 23 | 12 |
| Diclofenac Sodium | Diclofenac Sodium | 22 | 14 |
| Irbesartan | Irbesartan | 22 | suppressed |
| Nano 2nd Gen Pen Needle | Pen Needle, Diabetic | 22 | suppressed |
| Sucralfate | Sucralfate | 22 | suppressed |
| Sulfamethoxazole-Trimethoprim | Sulfamethoxazole/Trimethoprim | 22 | 16 |
| Estradiol | Estradiol | 21 | suppressed |
| Venlafaxine Hcl | Venlafaxine Hcl | 21 | suppressed |
| Aripiprazole | Aripiprazole | 20 | suppressed |
| Ciprofloxacin Hcl | Ciprofloxacin Hcl | 20 | 16 |
| Myrbetriq | Mirabegron | 20 | suppressed |
| Amoxicillin | Amoxicillin | 19 | 16 |
| Clobetasol Propionate | Clobetasol Propionate | 19 | suppressed |
| Methotrexate | Methotrexate Sodium | 19 | suppressed |
| Pioglitazone Hcl | Pioglitazone Hcl | 19 | suppressed |
| Rivastigmine | Rivastigmine | 19 | suppressed |
| Tresiba Flextouch U-100 | Insulin Degludec | 19 | suppressed |
| Anoro Ellipta | Umeclidinium Brm/Vilanterol Tr | 18 | suppressed |
| Benazepril Hcl | Benazepril Hcl | 18 | suppressed |
| Fluoxetine Hcl | Fluoxetine Hcl | 18 | suppressed |
| Nitroglycerin | Nitroglycerin | 18 | suppressed |
| Hydroxyzine Hcl | Hydroxyzine Hcl | 17 | suppressed |
| Lidocaine | Lidocaine | 17 | 13 |
| Tresiba Flextouch U-200 | Insulin Degludec | 17 | suppressed |
| Verapamil Er | Verapamil Hcl | 17 | suppressed |
| Desvenlafaxine Succinate Er | Desvenlafaxine Succinate | 16 | suppressed |
| Doxepin Hcl | Doxepin Hcl | 16 | suppressed |
| Lisinopril-Hydrochlorothiazide | Lisinopril/Hydrochlorothiazide | 16 | suppressed |
| Metronidazole | Metronidazole | 16 | 11 |
| Prolia | Denosumab | 16 | suppressed |
| Cholestyramine | Cholestyramine (With Sugar) | 15 | suppressed |
| Clonazepam | Clonazepam | 15 | suppressed |
| Ipratropium Bromide | Ipratropium Bromide | 15 | suppressed |
| Levetiracetam | Levetiracetam | 15 | suppressed |
| Lorazepam | Lorazepam | 15 | suppressed |
| Rybelsus | Semaglutide | 15 | suppressed |
| Triamterene-Hydrochlorothiazid | Triamterene/Hydrochlorothiazid | 15 | suppressed |
| Lamotrigine | Lamotrigine | 14 | suppressed |
| Lansoprazole | Lansoprazole | 14 | suppressed |
| Midodrine Hcl | Midodrine Hcl | 14 | suppressed |
| Rifampin | Rifampin | 14 | suppressed |
| Belsomra | Suvorexant | 13 | suppressed |
| Primidone | Primidone | 13 | suppressed |
| Amiodarone Hcl | Amiodarone Hcl | 12 | suppressed |
| Enalapril Maleate | Enalapril Maleate | 12 | suppressed |
| Entresto | Sacubitril/Valsartan | 12 | suppressed |
| Eplerenone | Eplerenone | 12 | suppressed |
| Ketoconazole | Ketoconazole | 12 | suppressed |
| Quetiapine Fumarate | Quetiapine Fumarate | 12 | suppressed |
| Symbicort | Budesonide/Formoterol Fumarate | 12 | suppressed |
| Baclofen | Baclofen | 11 | suppressed |
| Oseltamivir Phosphate | Oseltamivir Phosphate | 11 | 11 |
| Paroxetine Hcl | Paroxetine Hcl | 11 | suppressed |
| Teriparatide | Teriparatide | 11 | suppressed |
Timeline
Payment and prescribing data by year
Open Payments and Medicare Part D may refer to different years. They are shown separately rather than aligned as if they describe the same period.
| Year | General Payments | Main payer | Explicit products | Company overlaps | Part D coverage |
|---|---|---|---|---|---|
| 2025 | $2,185.03 · 96 records | Novo Nordisk Inc | ABRYSVO, ACCRUFER, AIRSUPRA, AREXVY, AVEIR, Assure WCD, BARRIGEL, BOTOX, BREZTRI, CAPVAXIVE, COMIRNATY, Cleerly Ischemia, Cleerly Labs, Dexcom G6 Transmitter, ELIQUIS, EVENITY, FARXIGA, FASENRA, FREESTYLE LIBRE 3, Fibroscan, GARDASIL 9, GEMTESA, INSPIRE, INTELLIS ADAPTIVESTIM, JARDIANCE, KISUNLA, Kerendia, LEQVIO, Leqembi, MOUNJARO, NURTEC ODT, Ozempic, PAXLOVID, PREVNAR 13, PREVNAR 20, QULIPTA, REPATHA, REXULTI, Rybelsus, SHINGRIX, SYNTHROID, TRELEGY ELLIPTA, UBRELVY, VRAYLAR, Veozah, WATCHMAN FLX, Wegovy, XIFAXAN, YUPELRI, ZAVZPRET, ZENPEP, Zypitamag | 12 | — |
| 2024 | — | — | — | — | Complete |
Questions to ask
Questions you could discuss with your doctor
- What role, if any, does Eliquis play in your treatment recommendations for me?
- How do you evaluate evidence when you have a financial relationship with ABBVIE INC.?
- Are there reasonable alternatives I should understand when we discuss treatment options?
- How should I interpret the industry-payment records shown here in the context of my care?
These are general questions generated from reviewed templates. They are not personalized medical advice.
Sources and limitations
How to read this page
- Payment and Medicare prescribing data can cover different years; every comparison shows both years explicitly.
- Part D does not represent a doctor’s entire practice; it excludes many patients and is subject to CMS public-release thresholds.
- Company–drug relationships must have an auditable source, a precise relationship type, and a valid evidence period. Unresolved mappings are not published.
- Generic drug claims are not attributed to a specific manufacturer without manufacturer-level evidence.
- When a source extract is incomplete, missing rows are never treated as proof of no payments or no prescriptions.
Loaded source releases
| Dataset | Year | Publication | Source |
|---|---|---|---|
| CMS Open Payments — General Payments | 2025 | 2026-06-30 | Original source |
| Medicare Part D Prescribers by Provider and Drug | 2024 | 2026-05-06 | Original source |
| NPPES Data Dissemination V2 | current / reference data | 2026-08-10 | Original source |
Full methodology · Questions & answers · Report a possible error